Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




European Diabetes Diagnostics Market

By HospiMedica staff writers
Posted on 26 Sep 2005
Spurred by new techniques that are making diabetes monitoring easier, the European market for diabetes diagnostics is forecast to grow from the current U.S.$265 million to $362 million by 2011, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), a global consulting company.

At least one-third of diabetics are ignorant of their condition. More...
For instance, up to a million of Europe's population with type 2 diabetes remain undiagnosed, creating an urgent need to improve public awareness of diabetes and to encourage regular monitoring. Furthermore, there is a need for improvement in physician and healthcare professional awareness and education in order to understand the complete benefits of laboratory-based testing and frequency.

As part of a public awareness campaign, patients need to be educated about the availability of novel tests and therapies. Innovative techniques are making diabetes monitoring much easier, and cutting-edge glucose meters that are compact and easy to handle are replacing imprecise traditional urine-based tests. These trends toward smaller size and ease of use represent attempts by manufacturers to improve patient accuracy, with components that require less time and blood to measure glucose.

Point-of-care (POC) testing, with its ability to provide rapid and simple results, offers an easy approach to regular monitoring of the disease and is already the largest market in Europe for diabetes diagnostics. While the levels of POC and laboratory testing will remain steady over the next several years, the use of glycated hemoglobin testing is expected to rise slightly as general practitioner surgeries, outpatient clinics, and small hospital-based laboratories adopt the technology more readily.

Nevertheless, the overall progress made in the diabetes diagnostics arena needs to be strengthened through continual efforts to achieve more patient-friendly screening and treatment, with emphasis on better education and training.




Related Links:
Frost & Sullivan

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.